What do systematic reviews say?

PAE vs sham

• Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 80 participants
  Moderate

Transurethral microwave thermotherapy vs transurethral resection of the prostate

• Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 306 participants
  Moderate

Transurethral microwave thermotherapy vs sham

• Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 483 participants
  Moderate

Combination therapy vs placebo

• Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1792 participants
  Low

Combination therapy vs anticholinergics

• Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 710 participants
  Very low

Combination therapy vs alpha‐blocker

• Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  19 studies · 3631 participants
  Very low

PAE vs TURP

• Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 360 participants
  Low

PAE vs TURP

• Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 176 participants
  Low

Aquablation vs transurethral resection of the prostate

• Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 174 participants
  Moderate

Silodosin vs placebo

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1743 participants
  Low

Silodosin vs naftopidil

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 652 participants
  Low

Silodosin vs alfuzosin

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Low

Silodosin vs tamsulosin

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1708 participants
  Low

Serenoa repens vs placebo or no intervention

Serenoa repens showed no clear difference in urologic symptom scoreMeasured by IPSS scores (range 0 to 35)Higher… compared with placebo or no intervention (high certainty).

• Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement 2023 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 1681 participants
  High

Serenoa repens in combination with other phytotherapy vs placebo or no intervention

Serenoa repens in combination with other phytotherapy showed no clear difference in urologic symptom scoreMeasured by IPSS scores (range 0 to 35)Higher… compared with placebo or no intervention (low certainty).

• Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 460 participants
  Low

PUL vs TURP

• Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 72 participants
  Low
• Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 69 participants
  Low

PUL vs sham

• Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 206 participants
  Low

Naftopidil vs tamsulosin

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  12 studies · 965 participants
  Moderate

Naftopidil vs propiverine (anticholinergic)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 37 participants
  Low

Naftopidil vs Eviprostat (phytotherapy)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 49 participants
  Moderate